Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake.
Vlachopoulos C, Koutagiar I, Skoumas I, Terentes-Printzios D, Zacharis E, Kolovou G, Stamatelopoulos K, Rallidis L, Katsiki N, Bilianou H, Liberopoulos E, Miliou A, Kafouris P, Georgakopoulos A, Gardikioti V, Tousoulis D, Anagnostopoulos CD. Vlachopoulos C, et al. Among authors: liberopoulos e. JACC Cardiovasc Imaging. 2019 Dec;12(12):2573-2574. doi: 10.1016/j.jcmg.2019.09.024. JACC Cardiovasc Imaging. 2019. PMID: 31806185 Free article. No abstract available.
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A, Alexandrides T, Alexopoulos D, Athyros V, Bargiota A, Bilianou E, Chrysochoou C, Drogari E, Elisaf M, Ganotakis E, Goudevenos I, Ioannidis I, Kolovou G, Kotsis V, Lekakis I, Liberopoulos E, Melidonis A, Nikolaou V, Ntaios G, Papanas N, Pappas S, Pitsavos C, Rallidis L, Richter D, Skoumas I, Tentolouris N, Tousoulis D, Tselepis A, Tsioufis K, Tziakas D, Tziomalos K, Vardas P, Vlachopoulos C, Vlahakos D. Achimastos A, et al. Among authors: liberopoulos e. Hormones (Athens). 2016 Jan-Mar;15(1):8-14. doi: 10.14310/horm.2002.1659. Hormones (Athens). 2016. PMID: 27086681 Free article.
A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study.
Alexopoulos D, Anastasiou-Nana M, Elisaf MS, Liberopoulos E, Rallidis LS, Davos CH, Moulis A, Nikas N, Zacharis E, Vardas P; CHALLENGE Investigators. Alexopoulos D, et al. Among authors: liberopoulos e. Int J Cardiol. 2016 Aug 15;217:183-9. doi: 10.1016/j.ijcard.2016.05.003. Epub 2016 May 3. Int J Cardiol. 2016. PMID: 27183455
An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN. Rizos CV, et al. Among authors: liberopoulos en. Hormones (Athens). 2017 Jul;16(3):200-204. doi: 10.14310/horm.2002.1749. Hormones (Athens). 2017. PMID: 29278517 Free article.
An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN. Rizos CV, et al. Among authors: liberopoulos en. Hormones (Athens). 2017 Jul;16(3):306-312. doi: 10.1007/BF03401525. Epub 2017 Nov 30. Hormones (Athens). 2017. PMID: 30091117
Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN. Rizos CV, et al. Among authors: liberopoulos en. Atherosclerosis. 2018 Oct;277:308-313. doi: 10.1016/j.atherosclerosis.2018.08.017. Atherosclerosis. 2018. PMID: 30270064
Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G, Diakoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, Liberopoulos EN, Matsouka F, Tsoutsinos A, Mastorakou I, Katsikas T, Mavrogeni S, Hatzigeorgiou G. Kolovou G, et al. Among authors: liberopoulos en. Eur J Prev Cardiol. 2020 Jan;27(2):157-165. doi: 10.1177/2047487319870007. Epub 2019 Aug 12. Eur J Prev Cardiol. 2020. PMID: 31403880
PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
Rallidis LS, Skoumas I, Liberopoulos EN, Vlachopoulos C, Kiouri E, Koutagiar I, Anastasiou G, Kosmas N, Elisaf MS, Tousoulis D, Iliodromitis E. Rallidis LS, et al. Among authors: liberopoulos en. Hellenic J Cardiol. 2020 Jul-Aug;61(4):241-245. doi: 10.1016/j.hjc.2019.10.003. Epub 2019 Nov 26. Hellenic J Cardiol. 2020. PMID: 31783124 Free article.
Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.
Rizos CV, Florentin M, Skoumas I, Tziomalos K, Rallidis L, Kotsis V, Athyros V, Skalidis E, Kolovou G, Garoufi A, Bilianou E, Koutagiar I, Agapakis D, Kiouri E, Antza C, Katsiki N, Zacharis E, Attilakos A, Sfikas G, Anagnostis P, Panagiotakos DB, Liberopoulos EN. Rizos CV, et al. Among authors: liberopoulos en. Lipids Health Dis. 2020 May 28;19(1):114. doi: 10.1186/s12944-020-01289-5. Lipids Health Dis. 2020. PMID: 32466791 Free PMC article.
Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
Rallidis LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, Kolovou G, Anastasiou G, Dima I, Tousoulis D, Iliodromitis E. Rallidis LS, et al. Among authors: liberopoulos en. Atherosclerosis. 2020 Sep;309:67-69. doi: 10.1016/j.atherosclerosis.2020.07.018. Epub 2020 Jul 30. Atherosclerosis. 2020. PMID: 32859385 No abstract available.
292 results